Maxim initiated coverage of Nuvectis Pharma (NVCT) with a Buy rating and $17 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCT:
- Nuvectis Pharma initiated with a Buy at Laidlaw
- Nuvectis announces new publication of research study on NXP900, osimertinib
- Nuvectis Pharma Reports 2024 Financial Results and Progress
- Nuvectis Pharma initiated with a Buy at Lucid Capital
- Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position